Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 6/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.39 |
| ▸ | PDE8A | O60658 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21117515 | 1.00 | HTR1A (0.46) | HTR1ADRD2HTR2AHTR7BACE1 | |
| SCHEMBL30279700 | 1.00 | HTR1A (0.46) | HTR1ADRD2HTR2AHTR7BACE1 | |
| SCHEMBL15091015 | 0.94 | HTR1A (0.41) | HTR1ADRD2HTR2AHTR7BACE1 | |
| SCHEMBL3925163 | 0.90 | ASIC3 (0.43) | HTR1ADRD2HTR2AHTR7CNR2 | |
| SCHEMBL29900984 | 0.90 | ASIC3 (0.43) | HTR1ADRD2HTR2AHTR7CNR2 | |
| SCHEMBL24565129 | 0.85 | HTR1A (0.53) | HTR1ADRD2HTR2AHTR7CNR2 | |
| SCHEMBL23028116 | 0.85 | HTR1A (0.53) | HTR1ADRD2HTR2AHTR7CNR2 | |
| SCHEMBL171452 | 0.81 | HRH4 (0.50) | HTR1ADRD2HRH4DRD4 | |
| SCHEMBL10008729 | 0.81 | HTR1A (0.53) | HTR1ADRD2CNR2CHRNA7MCHR1 | |
| SCHEMBL627837 | 0.79 | HTR1A (0.41) | HTR1ADRD2HTR2AHTR7CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120004785-A | Compounds and compositions for the treatment of diseases associated with STING activity | 诺华制药股份有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-112823036-B | Compounds and compositions for the treatment of diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-20240083895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11618749-B2 | Compounds and compositions for treating conditions associated with STING activity | IFM DUE, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| CN-112823036-A | Compounds and compositions for treating diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2021-05-18 | — | — | CN | disclosed |
| EP-3817820-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2021-05-12 | — | — | EP | disclosed |
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2020-06-04 | — | — | US | disclosed |
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | HTR1A 2306/4885DRD2 4335/4885HTR2A 1988/4885 |
| US-11618749-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, IRF3, CGAS | HTR1A 2417/4885DRD2 4480/4885HTR2A 2164/4885 |
| US-20240083895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | HTR1A 2306/4885DRD2 4335/4885HTR2A 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.